Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Non-Current Assets (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Non-Current Assets for 4 consecutive years, with $2.6 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-Current Assets fell 22.52% to $2.6 million in Q3 2024 year-over-year; TTM through Sep 2024 was $11.5 million, a 15.04% decrease, with the full-year FY2023 number at $3.2 million, down 2.09% from a year prior.
  • Non-Current Assets was $2.6 million for Q3 2024 at Actinium Pharmaceuticals, down from $2.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $3.5 million in Q2 2023 to a low of $509000.0 in Q1 2022.
  • A 4-year average of $2.5 million and a median of $3.0 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: crashed 62.3% in 2022, then skyrocketed 583.69% in 2023.
  • Actinium Pharmaceuticals' Non-Current Assets stood at $639000.0 in 2021, then surged by 408.61% to $3.2 million in 2022, then dropped by 2.09% to $3.2 million in 2023, then fell by 18.48% to $2.6 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Non-Current Assets are $2.6 million (Q3 2024), $2.8 million (Q2 2024), and $3.0 million (Q1 2024).